Is Predictive Oncology, Inc. overvalued or undervalued?

As of 14 August 2018, the valuation grade for Predictive Oncology, Inc. moved from does not qualify to risky, indicating heightened concerns regarding its financial health. The company appears to be overvalued based on its negative valuation ratios, including a Price to Book Value of -8.38, an EV to EBIT of -0.59, and an EV to EBITDA of -0.61. These figures suggest significant challenges in generating positive returns relative to its capital structure.
In comparison to its peers, Predictive Oncology's valuation ratios are notably weaker; for instance, Nutriband, Inc. has a much higher EV to EBITDA of -11.2912, while Nephros, Inc. boasts a strong P/E ratio of 31.3944, highlighting the disparity in financial performance within the sector. Despite a recent positive stock return of 20.39% year-to-date, which outperformed the S&P 500's 12.22%, the long-term performance remains concerning, with a staggering decline of 94.26% over five years. This combination of negative ratios and poor long-term performance reinforces the conclusion that Predictive Oncology, Inc. is overvalued.